"Medicare's Potential Shift on Obesity Medication Access"

Novo Nordisk's obesity drug Wegovy may soon be covered by Medicare after the FDA updated its prescription use to include reducing cardiovascular risks, potentially making it eligible for coverage under Medicare. While the change has not been officially implemented, drugmakers are lobbying Congress and pushing the FDA to approve the drug for conditions correlated with obesity. However, concerns remain about the drug's high cost, potential overuse, and side effects, prompting caution and the need for Medicare beneficiaries to compare coverage options during enrollment periods.